Recursion reports top-line SYCAMORE data, files Exscientia financials for proposed merger

RECURSION PHARMACEUTICALS, INC.

SYCAMORE Phase 2 trial for REC-994 in symptomatic CCM patients: top-line results announced Sept 3, 2024 (press release as Exhibit 99.2).
Filed audited financials of Exscientia for FY2023 and FY2022 (Exhibit 99.3) and unaudited interim statements for H1 2024 (Exhibit 99.4).
Filed pro forma condensed combined balance sheet as of June 30, 2024 and pro forma statements of operations (Exhibit 99.5).
Transaction closing deadline Aug 8, 2025; termination fees: Recursion $58.77M, Exscientia $6.88M; subject to HSR, court, stockholder votes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.